[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
Last updated December 3, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

634.P1.25 Myeloproliferative Syndromes Poster II

Oral and Poster Abstracts
Poster Session
Sunday, December 6, 2009: 6:00 PM-8:00 PM
Hall E (Ernest N. Morial Convention Center)
JAK2 Haplotype SNP Analysis in Essential Thrombocythemia: Clinical and JAK2V617F Allele Burden Correlates in 226 Patients

Animesh D. Pardanani, MBBS, PhD, Terra Lasho*, Christy Finke, BS*, Kebede Hussein, MD, Michelle Elliott, MB, BCh* and Ayalew Tefferi, MD

Hematology, Mayo Clinic, Rochester, MN

TET2 and ASXL1 Mutations in Leukemic Transformation of Chronic Myeloproliferative Neoplasms

Omar Abdel-Wahab1*, Taghi Manshouri2*, Jay Patel3*, Kelly Harris4*, Jin Juan Yao, MD, PhD5*, Cyrus V. Hedvat, MD, PhD6, Adriana Heguy4*, Carlos Bueso-Ramos7*, Hagop M. Kantarjian, MD8, Ross L. Levine, MD6 and Srdan Verstovsek, MD, PhD9

1Hematology and Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
2Leukemia, UT MD Anderson Cancer Center, Houston, TX
3Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, Sayville, NY
4Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY
5Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY
6Memorial Sloan-Kettering Cancer Center, New York, NY
7Leukemia, U.T. M.D. Anderson Cancer Center, Houston, TX
8Leukemia, MD Anderson Cancer Center, Houston, TX
9Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX

A JAK2 Germline Genetic Variation Is Associated with Shortened Survival in Primary Myelofibrosis:  Clinical and JAK2V617F Allele Burden Correlates of rs12343867 SNP Genotype in 132 Cases

Ayalew Tefferi, MD1, Terra Lasho2*, Christy Finke, BS1*, Kebede Hussein, MD1, Michelle Elliott, MB, BCh1* and Animesh D. Pardanani, MBBS, PhD1

1Hematology, Mayo Clinic, Rochester, MN
2Hematology, Mayo Clinic, Rochester

A Novel in Vitro Model of Focal Fibrosis in Bone Marrow Stromal Co-Culture of CD34+ Cells From Patients with Idiopathic Myelofibrosis

Jae Hung Shieh, PhD1, Richard T. Silver, MD2, Fernando Adriano, Clinical, Research, Nurse3* and Malcolm Moore, DPhil4*

1Memorial Sloan-Kettering Cancer Ctr., New York, NY
2Weill Cornell Medical College, New York, NY
3Hematology/Oncology, New York Hospital Weill Cornell, New York, NY
4Cell Biology, Memorial Sloan Kettering Cancer Center, New York, NY

Abnormal Expression and Function of the Lnk Adaptor Protein in Myeloproliferative Neoplasms (MPN)

Jean-Jacques Kiladjian, MD, PhD1*, Fanny Baran-Marszak, MD, PhD2*, Christophe Desterke, PhD3*, Bruno Cassinat, Pharm.D4*, Hajer Magdoud5*, Elisabeth Mazoyer, MD2*, Pierre Fenaux, MD, PhD6, Claude Gardin6*, Florence Cymbalista, MD, PhD2, Marie-Caroline Le Bousse-Kerdiles, PhD3*, Nadine Varin-Blank, PhD5* and Laura Velazquez, PhD5*

1Clinical Investigation Center (CIC), Hopital Saint-Louis & French Intergroup of Myeloproliferative disorders (FIM), Paris, France
2Laboratoire d'Hematologie, Hôpital Avicenne, APHP, Université Paris 13, Bobigny, France
3Inserm U972, University Paris 11, Villejuif, France
4Unite de Biologie Cellulaire, Hopital Saint-Louis, Paris, France
5INSERM U978 - Paris 13 University, Bobigny, France
6Hematologie Clinique, Assistance Publique - Hopitaux de Paris, Hopital Avicenne; Paris 13 University, Bobigny, France

Activity of Oral Panobinostat (LBH589) in Patients with Myelofibrosis

Daniel J. DeAngelo, MD, PhD1, Andrew Spencer2*, Thomas Fischer, MD3*, Thomas Kindler, MD3*, Oliver G. Ottmann, MD4*, Miles Prince, MD5, Frank J. Giles, MD, MB, FRCPI, FRCPath6, Jorge Cortes, MD7, Angela Liu, PharmD8*, Kathryn Parker, PhD8*, Ying Yan8*, Jeffrey W. Scott8* and Kapil N. Bhalla, MD9*

1Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
2Clinical Haematology & BMT, Alfred Hospital, Melbourne, Australia
33rd Medical Department, Johannes Gutenberg-University, Mainz, Germany
4Hematology and Oncology, Goethe Universität, Medizinische Klinik II, Frankfurt, Germany
5Department of Haematology, Peter MacCallum Cencer Centre, Melbourne, Australia
6Division of Hematology and Medical Oncology, University of Texas Health Science Center San Antonio, San Antonio, TX
7Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX
8Novartis Pharmaceuticals Corporation, East Hanover, NJ
9Department of Medicine, Medical College of Georgia Cancer Center, Augusta, GA

Aggressive Systemic Mastocytosis Is Associated with a High Kit D816V Allele Burden in Peripheral Blood

Philipp Erben, MD1*, Georg Bolz, MD1*, Juliana Popa, MD1*, Georgia Metzgeroth, MD1*, Martin C Müller, MD1*, Darko Gosenca, PhD1*, Thomas Ernst, MD2*, Wolf-Karsten Hofmann, MD1*, Andreas Hochhaus, MD3 and Andreas Reiter, MD1*

1III. Medizinische Klinik, Universitaetsmedizin Mannheim, 68167 Mannheim, Germany
2Wessex Regional Genetics Laboratory, University of Southampton, Salisbury, United Kingdom
3Universitätsklinikum Jena, Jena, Germany

Chromosomal Abnormalities in Transformed Ph-Negative Myeloproliferative Neoplasm Are Independent of the JAK2 and the TET2 Statuses

Florence Nguyen-Khac, MD, PhD1*, Lucile Couronne2*, Virginie Eclache3*, Joris Andrieux4*, Eric Lippert5*, Olivier Kosmider6*, Francine Mugneret7*, Marie-Agnes Collonge-Rame8*, Dominique Penther9*, Marina Lafage10*, Nathalie Gachard11*, Nathalie Nadal12*, Marie-Joelle Mozziconacci13*, Nicole Dastugue14*, Chrystele Bilhou-Nabera15*, Stephanie Struski14*, Christine Cabrol16*, Isabelle Radford-Weiss17*, Claude Lesty1* and Olivier A Bernard2*

1Hopital Pitie-Salpetriere, univ Paris 6, Paris, France
2Inserm E210, Hopital Necker-Enfants Malades, Paris, France
3Service d'Hematologie Biologique, AP-HP, université Paris XIII, Hopital Avicenne, Bobigny, France
4Hopital de Lille
5Laboratoire d'Hématologie, Centre Hospitalier Universitaire, Bordeaux, France
6INSERM U567, CNRS UMR8104, Département d'Hématologie, Institut Cochin, APHP Laboratoire d'Hématologie, Hôpital Cochin, Paris, France
7Laboratoire de Cytogénétique, CHU Dijon, Dijon, France
8Hopital de Besançon, Besançon, France
9Genetics, Centre Henri Becquerel, Rouen, France
10Cytogenetic, AP, Marseille, France
11Hopital de Limoges
12Hopital St-Etienne, St-Etienne, France
13Biopathologie, Institut Paoli-Calmettes, Marseille, France
14Laboratoire d'Hématologie, Hôpital Purpan, Toulouse, France
15Hopital Kremlin-Bicetre
16HU de Geneve, Geneve, Switzerland
17Hopital Necker-Enfants Malades, Paris, France

Comparison of Thalidomide and Lenalidomide for the Treatment of Patients (pts) with Myelofibrosis (MF)

Elias Jabbour, MD1, Hagop Kantarjian, MD1, Sameer A Parikh, MD1*, Deborah Thomas, MD1*, Tapan Kadia, MD2, Guillermo Garcia Manero, MD1*, Gautam Borthakur, MD1, Sherry Pierce, RN1*, Mark Brandt1*, Jorge Cortes, MD1 and Srdan Verstovsek, MD, PhD1

1Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX
2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Constitutive Heterozygous Expression of JAK2V617F Mutated Kinase Triggers Severe Myeloproliferative Disorder in Knock-in Mice

Caroline Marty1*, Catherine Lacout1*, Linda Fong1*, Antoine Martin2*, William Vainchenker, MD, PhD1 and Jean-Luc Villeval1*

1INSERM U790, Institut Gustave Roussy, Villejuif, France
2Service d'Anatomie et Cytologie Pathologiques, hôpital Avicenne, UFR SMBH Paris 13, Bobigny

Direct Binding of Grb2 Is Required for Efficient Induction of Myeloproliferative Disease in Mice by ETV6/FLT3

Kazuhisa Chonabayashi1*, Masakatsu Hishizawa1*, Shin Kawamata2*, Masashi Matsui1*, Tatsuharu Ohno3*, Takayuki Ishikawa1* and Takashi Uchiyama1

1Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
2Foundation for Biomedical Research and Innovation, Kobe, Japan
3Department of Internal Medicine, Ohtsu Red Cross Hospital, Ohtsu, Japan

Fatigue and Daily Life in Patients with Essential Thrombocythemia: Comparisons Between the USA and France in 447 Patients

Ruben A. Mesa, MD1, Jerome Rey, MD2*, Ayalew Tefferi, MD3, Joyce Niblack, JD4*, Pascal Lenain5*, Emmanuel Raffoux, MD6*, Thierry De Revel, MD, PhD7, John Camoriano, MD1 and Jean-Jacques Kiladjian, MD, PhD8*

1Mayo Clinic, Scottsdale, AZ
2Institute Paoli-Calmettes, Marseille, France
3Hematology, Mayo Clinic, Rochester, MN
4CMPD Education Foundation
5Service d'Hématologie, Centre Henri Becquerel, Rouen, France
6Dept. of Hematology, EA 3518, Université Paris VII, Hopital Saint Louis, AP-HP, Paris, France
7Dept. of Hematology, Hopital Percy, Clamart, France
8Clinical Investigation Center (CIC), Hopital Saint-Louis & French Intergroup of Myeloproliferative disorders (FIM), Paris, France

INCB018424, a Selective Inhibitor of JAK1 and JAK2, Downregulates the Expression of Leukocyte Alkaline Phosphatase (LAP) On Circulating Granulocytes in Patients with Polycythemia Vera and Essential Thrombocythemia

Francesco Passamonti1*, Elisa Rumi1*, Matteo G Della Porta1*, Monica Portolan1*, Chiara Elena1*, Luca Arcaini1*, Cristiana Pascutto1*, Laura Vanelli1*, Kris Vaddi2*, Mario Lazzarino1* and Mario Cazzola1

1Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
2Incyte Corporation, Wilmington, DE

Indolent Mastocytosis in 159 Adults: Smoldering but Not Bone Marrow Only Variant Is Prognostically Significant

Animesh D. Pardanani, MBBS, PhD1, Ken-Hong Lim, MD2*, Terra L Lasho, MT(ASCP)1*, Christy Finke, BS1*, Rebecca McClure, MD3, Chin Yang Li, MD3* and Ayalew Tefferi, MD1

1Hematology, Mayo Clinic, Rochester, MN
2Mackay Memorial Hospital, Taipei, Taiwan
3Hematopathology, Mayo Clinic, Rochester, MN

Inhibition of Cytokine Signaling through Activation of Jak2 Ubiquitination by WP1130

Vaibhav Kapuria1*, Luke F Peterson, PhD2*, William Bornmann, Ph.D.3*, Moshe Talpaz, MD2 and Nicholas J Donato2

1University of Michigan, Ann Arbor, MI
2Hematology/Oncology, University of Michigan, Ann Arbor, MI
3Experimental Therapeutics, M.D. Anderson Cancer Center, Houston, TX

Involvement of TET2 in Regulation of Epigenetic Silencing in MDS and Related Myeloid Malignancies

Hadrian Szpurka, PhD, MSc1, Anna M. Jankowska, MSc2*, Kwok Peng Ng, PhD3*, Joshua R. Clevenger3*, Yogen Saunthararajah, MD3 and Jaroslaw P. Maciejewski, MD, PhD3

1THOR, Taussig Cancer Institue, Cleveland Clinic, Cleveland, OH
2Department of Translational Hematology and Oncology Research, Cleveland Clinic,Taussig Cancer Institute, Cleveland, OH
3THOR, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

IPSS-Independent Cytogenetic Risk Categorization in Primary Myelofibrosis

Kebede Hussein, MD1, Animesh D. Pardanani, MBBS, PhD1, Daniel van Dyke2*, Curtis A. Hanson, MD3 and Ayalew Tefferi, MD1

1Division of Hematology, Mayo Clinic, Rochester, MN
2Division of Cytogenetics, Mayo Clinic, Rochester, MN
3Division of Hematopathology, Mayo Clinic, Rochester, MN

Long-Term Survival Data in 652 Patients with Primary Myelofibrosis or Polycythemia Vera— Trends in Recent Years

Rakhee Vaidya1*, Naseema Gangat, MD1, Sergio Siragusa, MD2, Susan Schwager1*, Curtis A. Hanson, MD3, Michelle Elliott, MB, BCh1*, Animesh D. Pardanani, MBBS, PhD1 and Ayalew Tefferi, MD1

1Hematology, Mayo Clinic, Rochester, MN
2Istituto di Ematologia, Policlinico Universitario di Palermo, Palermo, Italy
3Hematopathology, Mayo Clinic, Rochester, MN

Phase 1/2 Dose Finding Study of Pomalidomide in Myelofibrosis

Ruben A. Mesa, MD1, Animesh D. Pardanani, MBBS, PhD2, Kebede Hussein, MD3, Wenting Wu, PhD4*, Susan Schwager4*, Mark R. Litzow, MD2, William J Hogan, MD2 and Ayalew Tefferi, MD2

1Mayo Clinic, Scottsdale, AZ
2Hematology, Mayo Clinic, Rochester, MN
3Internal Medicine, Mayo Clinic, Rochester, MN
4Mayo Clinic, Rochester, MN

Sorafenib and Nilotinib Are Candidates to Overcome Imatinib Resistance in Myeloproliferation with FIP1L1-PDGFRA

Nikolas von Bubnoff, MD1*, Sivahari P Gorantla, MSc1*, Richard A. Engh, PhD2*, Taiana de Oliveira, PhD2*, Silvia Thoene, MSc3*, Espen Åberg, PhD2*, Christian Peschel, MD1 and Justus Duyster, MD1*

1III. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, München, Germany
2Departments of Chemistry and Pharmacy, University of Tromsø, Tromsø, Norway
3Medizinische Klinik und Poliklinik III, Klinikum Großhadern, Ludwig-Maximilians-Universität München, München, Germany

The Effects of SB1518, a Novel Oral JAK2 Inhibitor, On Ex Vivo Expanded PV Erythroid Progenitors Correlate with Clinical Observations

Kee Chuan Goh, Ph.D.1*, Stefan Hart, Ph.D.1*, Yong Cheng Tan, M.Sc.1*, Amalini Chithra, B.Sc.1*, Kiat H. Ong, MBBS, MRCP, FRCPA2 and Jeanette Wood, PhD3*

1Biology, S*BIO PTE LTD, Singapore, Singapore
2Dept of Laboratory Medicine, Tan Tock Seng Hospital, Singapore, Singapore
3S*BIO PTE LTD, Singapore, Singapore

The mTOR Inhibitor, RAD001, Inhibits the Growth of Cells From Patients with Myeloproliferative Neoplasms

Alessandro M. Vannucchi, MD, Costanza Bogani, PhD*, Niccolò Bartalucci, BSc*, Paola Guglielmelli, MD*, Lorenzo Tozzi, BSc*, Elisabetta Antonioli, MD*, Lisa Pieri, MD* and Alberto Bosi, MD*

Hematology, Universitá degli Studi di Firenze, Firenze, Italy

Thrombosis in Primary Myelofibrosis: Incidence and Risk Factors

Tiziano Barbui1*, Alessandra Carobbio1*, Francisco Cervantes2*, Alessandro M. Vannucchi, MD3, Paola Guglielmelli, MD3*, Elisabetta Antonioli, MD4*, Alberto Alvarez-Larràn2*, Alessandro Rambaldi1, Guido Finazzi1* and Giovanni Barosi5*

1Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
2Hematology, Hospital Clinic, Barcelona, Spain
3Hematology, Universitá degli Studi di Firenze, Firenze, Italy
4Hematology, Università  degli Studi di Firenze, Firenze, Italy
5Center for the Study of Myelofibrosis, IRCCS S. Matteo, Pavia, Italy

Thrombotic Complications and Risk of Myeloid Transformation in 164 Elderly Patients with Essential Thrombocythemia

Erica Peterson, M.Sc., M.D.1*, Leslie Zypchen, MD2, Janet Nitta2*, Jonathan Berkowitz, M.Sc., Ph.D.2* and Lynda M Foltz, MD3*

1Department of Medicine, University of British Columbia, Vancouver, BC, Canada
2Division of Hematology, University of British Columbia, Vancouver, BC, Canada
3Division of Hematology, St. Paul's Hospital, Vancouver, BC, Canada

Tumor Necrosis Factor-Alpha (TNF) Expression Is Elevated in Myelo-Proliferative Neoplasms (MPN) and Modulated by Inhibition of JAK2 V617F

Karl J. Aichberger, MD, PhD1*, Angela G. Fleischman, MD, PhD2, Shirin Doratotaj, MD2*, Thomas G.P. Bumm, MD3*, Richard T. Silver, MD4, Thomas G. Deloughery, MD5, Heike L. Pahl, PhD6*, Brian J. Druker, MD7, Christopher J. Burns8* and Michael Deininger, MD, PhD9

1Medical University of Vienna, Vienna, Austria
2OHSU Cancer Institute, Oregon Health and Science University, Portland, OR
3Center for Hematologic Malignancies, Oregon Health & Science University, Portland, OR
4Weill Cornell Medical College, New York, NY
5Oregon Health and Science Univ., Portland, OR
6University Hospital Freiburg, Freiburg, Germany
7Oregon Health & Science University Knight Cancer Institute, Portland, OR
8Cytopia Research Pty Ltd, Melbourne, Victoria, Australia, Richmond, Australia
9Knight Cancer Institute, Oregon Health & Science University, Portland, OR

*signifies non-member of ASH